Results from phase II [23] and phase III [24] clinical trials have shown the efficacy of T-DXd in patients with metastatic HER2+ breast cancer, with a higher response rate, longer PFS, and higher survival rate at 1 year than TDM-1 [25]. This evidence concerns the gene ERBB2 and breast carcinoma.